TY - JOUR A1 - Godard, A. A1 - Kalot, G. A1 - Pliquett, J. A1 - Busser, B. A1 - Le Guével, X. A1 - Wegner, Karl David A1 - Resch-Genger, Ute A1 - Russelin, Y. A1 - Coll, J.-L. A1 - Denat, F. A1 - Bodio, E. A1 - Goze, C. A1 - Sancey, L. T1 - Water-Soluble Aza-BODIPYs: Biocompatible Organic Dyes for High Contrast In Vivo NIR-II Imaging JF - Bioconjugate Chemistry N2 - A simple NIR-II emitting water-soluble system has been developed and applied in vitro and in vivo. In vitro, the fluorophore quickly accumulated in 2D and 3D cell cultures and rapidly reached the tumor in rodents, showing high NIR-II contrast for up to 1 week. This very efficient probe possesses all the qualities necessary for translation to the clinic as well as for the development of NIR-II emitting materials. KW - Aza-BODIPY KW - NIR-II Imaging KW - In vivo imaging KW - organic dyes KW - SWIR KW - Cancer KW - Fluorescence PY - 2020 DO - https://doi.org/10.1021/acs.bioconjchem.0c00175 VL - 31 IS - 4 SP - 1088 EP - 1092 PB - ACS Publications AN - OPUS4-50695 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - JOUR A1 - Godard, A. A1 - Kalot, G. A1 - Privat, M. A1 - Bendellaa, M. A1 - Busser, B. A1 - Wegner, Karl David A1 - Denat, F. A1 - Le Guevel, X. A1 - Coll, J.-L. A1 - Paul, C. A1 - Bodio, E. A1 - Goze, C. A1 - Sancey, L. T1 - NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer JF - Journal of Medicinal Chemistry N2 - Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thus their potential for NIR-II FGS in the cancer setting. KW - NIR-II KW - Fluorescent dye KW - In vivo imaging KW - Ovarian cancer KW - Antibody conjuagtes KW - Bioimaging PY - 2023 DO - https://doi.org/10.1021/acs.jmedchem.3c00100 SN - 0022-2623 VL - 66 IS - 7 SP - 5185 EP - 5195 PB - ACS Publications AN - OPUS4-57293 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -